Komori
Daito Pharmaceutical (4577) · RiskMitigated

Risk of customer confidential information leaks

First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2022.

4entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20182016: 120162017: 120172018: 120182019: 020192020: 020202021: 020212022: 12022
Same theme, other companies
Risk of leakage of information on development candidates and business operationsA theme 28 companies write about · 27 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2020: 1 of 10 companies on the "Worse" side.

3 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 28 companies compared. The sentences above are computed from all 28.
Full recordFilings, disclosures and news, newest first
  1. FY2022MitigatedAnnual report

    「To address these risks, the Group has established rules and other measures for information management, thoroughly communicated the importance of information management to employees, and worked to prevent information leaks.」

    In response to the risk of leaks of customers’ production plans, new product development information and other confidential information, the company describes establishing information management rules and thoroughly communicating them to employees.
  2. FY2018RestatedAnnual report

    「If an information leak or similar incident occurs for any reason, the Group’s operating results and other aspects of its performance may be affected by damage to its reputation and other consequences.」

    The risk of leaks of confidential information, including customers’ production plans and new product development information, has been reiterated.
  3. FY2017RestatedAnnual report

    「If an information leak or similar incident occurs for any reason, the Group’s operating results and other aspects of its performance may be affected by damage to its reputation and other consequences.」

    The risk of leaks of confidential information, including customers’ production plans and new product development information, has been reiterated.
  4. FY2016First statedAnnual report

    「If an information leak or similar incident occurs for any reason, the Group’s operating results and other aspects of its performance may be affected by damage to its reputation and other consequences.」

    This risk is based on the nature of the business, which involves obtaining customers’ production plans and information on new product development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of customer confidential information leaks | Daito Pharmaceutical Co.,Ltd. (4577) | Komori